default author photo

Ursula Vehling-Kaiser

Tagesklinik Landshut

Landshut

Germany

SCHOLARLY PAPERS

1

DOWNLOADS

44

TOTAL CITATIONS

2

Scholarly Papers (1)

1.

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

Number of pages: 151 Posted: 23 Feb 2019
University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Würzburg, Tagesklinik Landshut, University of Duisburg-Essen - University Hospital Essen, University Hospital Ulm, Mannheimer Onkologie Praxis, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, University of Cologne - Department I of Internal Medicine, Schleswig-Holstein University - University Hospital Center, Schleswig-Holstein University - University Hospital Center, Schleswig-Holstein University - University Hospital Center, University of Cologne - Department I of Internal Medicine, University Hospital Ulm, University of Cologne - Department I of Internal Medicine and University of Cologne - Department I of Internal Medicine
Downloads 44 (1,133,231)
Citation 2

Abstract:

Loading...

chronic lymphocytic leukaemia, ibrutinib, ofatumumab, benadmustine